Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:It’s allllllll talk

[CancerSlayer]

Infinity wrote: A very likely and all familiar scenario that keep repeating itself.  Just next quarter,  hang in there!!  everything is going to be OK!!.  I hope after this raise RDW thinks seriously in terms of a JV instead of going it alone.

From an investor's standpoint, both our partnership/financing options will certainly depend on the amount of this latest raise/tranche.  

We shouldn't need a jv to reach BTD. Such a milestone can act as a stronger proof point for big & small suitors, enabling better partnering & funding deals (i.e. royalty/licensing, convertible debt financing).  

In terms of partnering, I fear Big Pharma will try to devour us for pennies on the dollar while we exist in the pre-commercial stages (with or w/o BTD).  I think at minimum, we will need an AA to get us a more satisfactory premium on sp.

As we sit in the clinical stages of development, it may be worth looking at alternative partners....and sitting on this exchange certainly won't help us deal with our dual threat of cash & valuation contraints/challenges.  Perhaps a biotech-to-biotech deal could be a viable option at this clinical stage in order to achieve the benefits of scale w/o giving up the farm?  Partnering with a well-capitalized biotech that has a complementary platform, or one that has a weaker pipeline but better capitalized, could open up some interesting opportunities/potential imo.  

The above type of partnership &/or licensing deals would be my go-to at this clinical stage, especially if you don't want to give up too much control over your IP.  

In the event we are still financially challenged after this next raise, operational efficiency should take a front seat in terms of further streamlining/reducing overall OPEX, particularly admin expenses.  I'd personally like to see admin costs run lower (at < 30% of total expenses), especially considering we are a pre-commercial stage company...jmo.

Having said that, my hat is off for mgmt having been able to run this operation to date on such a shoestring budget...a rare feat in this industry.  In the meantime, investor scrutiny should be considered healthy & welcomed while we remain fiscally constrained & while having such promising R&D/pipelines, not to mention significant investor investment & confidence. My personal rule of thumb is that a promising &/or successful biotech should always ensure a clear/equitable connection between asset allocation & value creation.  All imo & best of luck longs...